SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* OrbiMed Capital GP V LLC (Last) (First) (Middle) 601 LEXINGTON AVENUE 54TH FLOOR (Street) NEW YORK NY 10022-4629 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 09/15/2020	3. Issuer Name and Ticker or Trading Symbol Adicet Bio, Inc. [ ACET ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities are beneficially owned	0(1)	I(1)	See Footnote(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person* OrbiMed Capital GP V LLC (Last) (First) (Middle) 601 LEXINGTON AVENUE 54TH FLOOR (Street) NEW YORK NY 10022-4629 (City) (State) (Zip)

1. Name and Address of Reporting Person* OrbiMed Advisors Israel II Ltd (Last) (First) (Middle) 89 MEDINAT HAYEHUDIM ST., BUILDING E (Street) HERZLIYA L3 4614001 (City) (State) (Zip)

1. Name and Address of Reporting Person* OrbiMed Israel GP II, L.P. (Last) (First) (Middle) 89 MEDINAT HAYEHUDIM ST., BUILDING E (Street) HERZLIYA L3 4614001 (City) (State) (Zip)

1. Name and Address of Reporting Person* OrbiMed Israel GP Ltd. (Last) (First) (Middle) 89 MEDINAT HAYEHUDIM ST., BUILDING E (Street) HERZLIYA L3 4614001 (City) (State) (Zip)

1. Name and Address of Reporting Person* OrbiMed Israel BioFund GP Limited Partnership (Last) (First) (Middle) 89 MEDINAT HAYEHUDIM ST., BUILDING E (Street) HERZLIYA L3 4614001 (City) (State) (Zip)

Explanation of Responses:

1. This report is being jointly filed by OrbiMed Capital GP V LLC, OrbiMed Israel BioFund GP Limited, OrbiMed Israel GP Ltd., OrbiMed Israel Partners II, L.P., and OrbiMed Israel GP II, L.P. The Reporting Persons have designated Carl L. Gordon ("Gordon") and Erez Chimovits ("Chimovits") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of the Issuer's securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

	OrbiMed Capital GP V LLC, /s/ Douglas Coon, Chief Compliance Officer	09/17/2020
	OrbiMed Israel BioFund GP Limited, /s/ Douglas Coon, Chief Compliance Officer	09/17/2020
	OrbiMed Israel GP Ltd., /s/ Douglas Coon, Chief Compliance Officer	09/17/2020
	OrbiMed Israel Partners II, L.P., /s/ Douglas Coon, Chief Compliance Officer	09/17/2020
	OrbiMed Israel GP II, L.P., /s/ Douglas Coon, Chief Compliance Officer	09/17/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.